A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS).

This study is a clinical trial, which means it's a careful research study involving people. It's looking into a new treatment for Polycystic Ovary Syndrome (PCOS), a common condition affecting many women. PCOS can cause various symptoms like irregular periods, difficulty getting pregnant, acne, and excess hair growth. Current treatments often help manage these symptoms, but researchers are always looking for better options.

The new treatment being tested is a combination of existing medicines called SPIOMET. This study is in Phase II, which means it's one of the earlier stages of research. Scientists are focused on finding out if the treatment works as intended, mainly by seeing if it helps women with PCOS to ovulate more regularly. Ovulation is when an egg is released from the ovary, a key part of a regular menstrual cycle. They will be comparing SPIOMET to individual medications or a dummy pill (placebo) to understand its effects better.

Beyond ovulation, the research team will also be keeping a close eye on other important aspects of health. This includes checking general health measures like weight, blood pressure, and hormone levels, which are often affected by PCOS. They will also look at how the body handles sugar and fats, and even use scans like MRI to see how the treatment might affect body composition and fat distribution. Importantly, they will carefully monitor for any side effects to make sure the treatment is safe and well-tolerated for those who take it. The aim is to find new and effective ways to help manage PCOS and improve the lives of young women with the condition.